Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. (PRVCF) is an innovative health sciences company developing preventive and curative therapies through advanced biotechnology research. This page serves as the definitive source for verified news and official updates about the company's scientific advancements and corporate developments.
Investors and researchers will find timely updates on PRVCF's progress across multiple therapeutic programs, including its nature-identical peptide research, Sol-Gel drug delivery platform, and non-addictive pain management solutions. Our curated news feed ensures stakeholders stay informed about material events including clinical trial milestones, intellectual property filings, and strategic partnership announcements.
The news collection focuses on three key areas: Research Breakthroughs (gene therapy progress, preclinical study results), Operational Updates (regulatory filings, financial disclosures), and Strategic Developments (collaborations, patent grants). Each update is verified against original source materials to ensure accuracy.
Bookmark this page for streamlined access to PRVCF's latest advancements in preventive health sciences. For comprehensive analysis of how these developments may impact long-term research trajectories, consider subscribing to our investment research updates.
PreveCeutical Medical Inc. (OTCQB: PRVCF) has appointed Dr. Francis Tavares as Chief Technology Officer, effective June 27, 2025. Dr. Tavares brings over three decades of experience in organic and medical chemistry, and drug discovery to the company.
Dr. Tavares most recently served as President and CEO of ChemoGenics BioPharma, where he led drug discovery initiatives resulting in the commercialization of Trilaciclib and successful Phase 3 clinical trials of Lerociclib, a CDK4/6 inhibitor. His career includes significant achievements at GlaxoSmithKline, where he received the Excellence in Science Award in 2004, and the successful establishment of ChemoGenics BioPharma.
The appointment strengthens PreveCeutical's leadership team as the company continues its development of preventive and curative therapies using organic and nature-identical products.
PreveCeutical Medical (OTCQB: PRVCF) has scheduled its annual general and special meeting for August 15, 2025. Shareholders will vote on director elections, auditor appointments, and notably, a plan to distribute up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders.
The arrangement will result in shareholders owning stakes in two separate companies: BioGene, focusing on Dual Gene Therapy program development, and PreveCeutical, continuing its focus on preventive and curative therapies using organic products. This strategic separation aims to expand both companies' shareholder bases and improve access to capital for research and development.
PreveCeutical Medical (OTCQB: PRVCF) has appointed Stephen Glover as Corporate Advisor, effective May 24, 2025. The health sciences company, which focuses on developing innovative preventive and curative therapies using organic and nature-identical products, expects to benefit from Glover's extensive experience in biopharma, corporate strategy, commercialization, and financial management. CEO Stephen Van Deventer emphasized Glover's proven leadership and track record in building and transforming organizations as key assets for advancing PreveCeutical's therapeutic development mission.
PreveCeutical Medical Inc. (PRVCF) has announced the launch of a new website for its majority-owned subsidiary, BioGene Therapeutics Inc., a Texas-based life sciences company. The website aims to showcase BioGene's research and development initiatives, particularly focusing on metabolic health and gene-based treatments.
Through its wholly-owned subsidiary BioGene Australia, the company is conducting research on GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies targeting the global diabetes and obesity crisis. The website launch is part of BioGene's growth strategy to enhance stakeholder communication and industry engagement.
PreveCeutical Medical Inc. (PRVCF) has announced a new program to develop their Nose to Brain (N2B) Sol-Gel platform for delivering Dopamine and L-Dopa directly to the brain for Parkinson's disease treatment. The technology is designed to bypass the Blood Brain Barrier (BBB), which could potentially improve drug bioavailability while reducing side effects associated with current delivery methods.
The company expects this approach to enhance safety and effectiveness by avoiding systemic exposure and requiring lower therapeutic doses through direct brain targeting. The N2B platform's ability to bypass other body compartments could lead to reduced drug dosages and improved patient compliance.
PreveCeutical plans to demonstrate proof of concept in preclinical models before seeking partnerships with organizations specializing in Parkinson's disease.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has appointed Dr. Bryan Jones as Director of Sol-Gel Special Projects, effective January 31, 2025. Dr. Jones brings over 30 years of drug development experience and currently serves as Chief Operating Officer of Aardvark Therapeutics. His extensive background includes co-founding Sollis Therapeutics and Sherrington Pharmaceuticals, with experience at Bristol-Myers Squibb and work on products like Cialis.
Dr. Jones holds a Ph.D. in Genetics from the University of Washington and will focus on advancing PreveCeutical's Sol-Gel program for Nose to Brain delivery of therapeutics. The company aims to develop preventive and curative therapies using organic and nature identical products. CEO Stephen Van Deventer expressed that Dr. Jones's expertise will help accelerate the program, with details on their first targeted therapeutic forthcoming.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced that its subsidiary BioGene Therapeutics will participate in the 43rd JP Morgan Healthcare Conference from January 13-16, 2025, in San Francisco.
The company's leadership team attending includes Dr. Harry Parekh (Chief Research Officer & Scientific Founder), along with board members Dr. Deepak Sampath, Steve Glover, and Patroski J. Lawson. BioGene, under parent company PreveCeutical, focuses on developing innovative preventive and curative therapies using organic and nature-identical products.
CEO Stephen Van Deventer emphasized the importance of having their Scientific Founder and experienced team members present to showcase their accomplishments and future plans. Interested parties can request meetings with the team via info@biogenetherapeutics.com.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) has announced a change in its auditing firm. The company's board of directors has accepted the resignation of Smythe LLP as their former auditor and appointed Davidson & Company LLP as the successor auditor, effective December 18, 2024. The new auditor will serve until the company's next annual general meeting of shareholders.
The company confirms there were no reservations in the former auditor's reports during their tenure, and no reportable events exist between PreveCeutical and Smythe LLP. The required documentation, including the Notice of Change of Auditor and letters from both auditing firms, has been reviewed by the audit committee and board of directors and will be filed on SEDAR.
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Patroski J. Lawson as an independent director effective December 6, 2024. According to CEO Stephen Van Deventer, Lawson brings extensive experience in government affairs across local, state, federal, and global levels, particularly within the healthcare sector. The company expects his strategic insights and leadership to strengthen their governance and advocacy efforts as they navigate the regulatory landscape in developing innovative therapies.
FAQ
What is the current stock price of Preveceutical (PRVCF)?
What is the market cap of Preveceutical (PRVCF)?
